INDIVIDUAL ARTICLE: Real-World Clinical Experience With a Neuro-Peptide Serum in Combination With Botulinum Toxin Type-A Injections
November 2024 | Volume 23 | Issue 11 | 43661s3 | Copyright © November 2024
Published online October 29, 2024
Mark Lupin MD FRCPCa, Peter Bjerring MD Dr Scib, Anneke Andriessen PhDc, Jonquille Chantrey MDd, Sabrina Guillen Fabi MD FAAD FAACSe, Steven Liew MDf, Cara McDonald MBBS BMedSci MPH FACDg, Qin Xiaolei MDh, Stacy White PhDi
aCosmedica Laser Centre, Victoria, BC, Canada
bDepartment of Dermatology, Aalborg University Hospital, Aalborg, Denmark
cRadboud UMC Nijmegen, Andriessen Consultants, Malden, The Netherlands
dØNE aesthetic studiø, Alderley Edge, Cheshire, United Kingdom
eCosmetic Laser Dermatology, San Diego;
University of California, San Diego, CA
fShape clinic, Medical Director, Specialist Plastic Surgeon, Sydney, Australia
gSt Vincent's Hospital, Director Complete Skin Specialists, Sunbury, Melbourne, Australia
hDEYI SKIN Dermatology Clinic, Shenzhen, China; iSkinCeuticals, New York, NY
Abstract
We evaluated real-life experiences of a topical neuro-peptide serum containing 2% acetyl hexapeptide-8, 2% dipeptide diaminobutyroyl, 5% polyhydroxy acids (PHA), 5% niacinamide, and 1% laminaria extract (topical neuro-peptide serum [TNP-serum]). The TNP-serum works synergistically by stimulating 9 key skin biomarkers to reduce wrinkles and produce a skin-brightening effect. Here, we highlight the real-life experiences of 5 dermatologists and 2 surgeons, using an integrated skincare regimen consisting of botulinum toxin type-A (BTX-A) injection in conjunction with twice daily TNP-serum. Real-world cases provide evidence for combination treatments that may be used in cosmetic dermatology to improve patient outcomes and satisfaction. TNP-serum appears to complement BTX-A injections to improve radiance, reduce fine lines, and reduce wrinkles in diverse patients. Incorporating TNP-serum into integrated skincare regimens may offer an additive effect to BTX-A injections and, ultimately, optimize patient results.
J Drugs Dermatol. 2024;23:11(Suppl 2):s3-14.
INTRODUCTION
By 2050, the World Health Organization (WHO) estimates that the world's population of people aged 65 years and older will have more than doubled from 761 million in 2021.1 As the population and their skin ages, there will be an increasing demand for targeted treatments for skin rejuvenation. Skin ages in response to intrinsic and extrinsic factors.2 Intrinsic aging occurs with chronological age and may be affected by hormonal status and comorbid disease.2 Extrinsic aging occurs due to ultraviolet (UV) exposures, cigarette smoking, and other environmental factors.2 It is estimated that over 80% of facial skin aging is due to long-term UV exposure that leads to skin roughening, wrinkling, dyschromia, and loss of skin elasticity.3 Together, extrinsic and intrinsic factors lead to epidermal thinning, loss of elasticity, skin fragility, and wrinkles.
While benign, wrinkles can be particularly distressing for some patients and negatively impact their self-image and quality of life.4 They form due to age-related dermal atrophy and repetitive contraction of muscles that may lead to wrinkling of the overlying skin.4 Fine wrinkles (<1 mm in width and depth) and coarse wrinkles (>1 mm) can occur anywhere on the body, but have been most studied on the face, forearms, and hands.4 On the face, dynamic wrinkles form perpendicular to the direction of muscle contraction.4 Common dynamic wrinkles that are often treated include horizontal forehead lines, bunny lines (nasal lines), radial lip lines, marionette lines, frown lines, crow's feet (lateral canthal lines), accordion smile lines (cheek folds), nasolabial fold lines, and chin lines (Figure 1).4
